294 related articles for article (PubMed ID: 25658618)
1. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.
Crosson JN; Laird PW; Debiec M; Bergstrom CS; Lawson DH; Yeh S
J Immunother; 2015; 38(2):80-4. PubMed ID: 25658618
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.
Bricout M; Petre A; Amini-Adle M; Bezza W; Seve P; Kodjikian L; Dalle S; Thomas L
J Immunother; 2017; 40(2):77-82. PubMed ID: 28166182
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.
Monferrer-Adsuara C; Hernández-Bel L; Hernández-Garfella ML; Remolí-Sargues L; Ortiz-Salvador M; Castro-Navarro V; Cervera-Taulet E
Optom Vis Sci; 2021 Nov; 98(11):1309-1316. PubMed ID: 34510146
[TBL] [Abstract][Full Text] [Related]
4. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease.
Sugita S; Sagawa K; Mochizuki M; Shichijo S; Itoh K
Int Immunol; 1996 May; 8(5):799-803. PubMed ID: 8671669
[TBL] [Abstract][Full Text] [Related]
5. Vogt-Koyanagi-Harada syndrome--isolation of cloned T cells with specificity for melanocytes and melanoma cells.
McClellan KA; MacDonald M; Hersey P; Billson FA
Aust N Z J Ophthalmol; 1989 Nov; 17(4):347-52. PubMed ID: 2624724
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
Witmer MT
Ophthalmic Surg Lasers Imaging Retina; 2017 Nov; 48(11):928-931. PubMed ID: 29121363
[TBL] [Abstract][Full Text] [Related]
7. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.
Fujimura T; Kambayashi Y; Tanita K; Sato Y; Hidaka T; Otsuka A; Tanaka H; Furudate S; Hashimoto A; Aiba S
J Dermatol; 2018 Jun; 45(6):735-737. PubMed ID: 29488243
[TBL] [Abstract][Full Text] [Related]
8. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
[TBL] [Abstract][Full Text] [Related]
9. Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient.
Abad S; Wieërs G; Colau D; Wildmann C; Delair E; Dhote R; Brézin AP; Kawakami Y; Coulie PG; van der Bruggen P
Mol Vis; 2014; 20():956-69. PubMed ID: 24991188
[TBL] [Abstract][Full Text] [Related]
10. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Yeh S; Karne NK; Kerkar SP; Heller CK; Palmer DC; Johnson LA; Li Z; Bishop RJ; Wong WT; Sherry RM; Yang JC; Dudley ME; Restifo NP; Rosenberg SA; Nussenblatt RB
Ophthalmology; 2009 May; 116(5):981-989.e1. PubMed ID: 19410956
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
13. Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma.
Fusumae T; Kamiya K; Maekawa T; Komine M; Murata S; Inoda S; Takahashi R; Kawashima H; Ohtsuki M
J Dermatol; 2018 Jun; 45(6):e159-e160. PubMed ID: 29314171
[No Abstract] [Full Text] [Related]
14. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
Klein O; Ebert LM; Nicholaou T; Browning J; Russell SE; Zuber M; Jackson HM; Dimopoulos N; Tan BS; Hoos A; Luescher IF; Davis ID; Chen W; Cebon J
Clin Cancer Res; 2009 Apr; 15(7):2507-13. PubMed ID: 19318477
[TBL] [Abstract][Full Text] [Related]
15. Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up.
Aisenbrey S; Lüke C; Ayertey HD; Grisanti S; Perniok A; Brunner R
Graefes Arch Clin Exp Ophthalmol; 2003 Dec; 241(12):996-9. PubMed ID: 14618342
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma.
du Rusquec P; Saint-Jean M; Brocard A; Peuvrel L; Khammari A; Quéreux G; Dréno B
J Immunother; 2014; 37(6):348-50. PubMed ID: 24911795
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
Ascierto PA
Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
[TBL] [Abstract][Full Text] [Related]
18. A case report of orbital inflammatory syndrome secondary to ipilimumab.
Henderson AD; Thomas DA
Ophthalmic Plast Reconstr Surg; 2015; 31(3):e68-70. PubMed ID: 24814274
[TBL] [Abstract][Full Text] [Related]
19. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
20. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]